Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

Part of paid clinical trials in Pompano Beach, Florida.

Sponsor
SFA Therapeutics
Study ID
NCT05642182
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SFA002 — DRUG
    Study drug formula without excipient
  • SFA002 — DRUG
    Study Drug SFA002 with excipient (Propionate)

Study Details

The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.

Key Dates

Start date
Mar 31, 2022
Status verified
Jan 2025
Primary completion
Jul 30, 2025
Completion
Jul 31, 2025

Study Design

Enrollment
90 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Drug (SFA002) Formula 1
  • Experimental: Drug (SFA002) Formula 2

Primary Outcome Measure

Psoriasis Area and Severity Index (PASI) Score [ Time Frame: From enrollment to final visit at 24 weeks treatment and 4 week follow-up ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
NuLine Clinical Trial CenterPompano BeachFlorida33060
Thalyat Jones
[email protected]
855 501-1071
Axis Clincals USA/ Red River Research Patners. LLCFargoNorth Dakota58104
Kristen Peterson
[email protected]
701-866-3026
Michael Blankenship, MD
Temple UniversityPhiladelphiaPennsylvania19140
Sarmina Hassan, PhD
215-707-1934

Find similar trials in Pompano Beach, FL

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
NuLine Clinical Trial Center· Pompano Beach, FLAxis Clincals USA/ Red River Research Patners. LLC· Fargo, NDTemple University· Philadelphia, PA

Related Studies